Casgevy also now indicated for transfusion-dependent beta thalassemia in children 2 years ...

Casgevy sickle cell gene therapy is now FDA-approved for children as young as two, opening access for 5,500 more U.S. kids.

Recent data published in NEJM demonstrates that CRISPR gene-editing therapy achieves complete clinical efficacy endpoints in ...

The CRISPR-based drug development platforms market capitalizes on the growing demand for precision medicine and gene editing advancements, especially in oncology. Opportunities lie in enhanced drug ...

For the first time, children in the US as young as two with the blood disorders sickle cell disease and beta thalassaemia are ...

Manufacturers are developing platform technologies for personalized CRISPR gene-editing therapies following the Baby KJ case.

Explore the revolutionary potential of biotechnology and gene editing, alongside crucial ethical considerations and ...

Gene editing has delivered remarkable results against sickle cell disease. Now researchers are working to make these ...

A handful of start-up firms are testing therapies that target specific epigenetic markers to treat everything from high ...

Daniel Cressy, 23, has become the first person in the Gulf South to become functionally cured of sickle cell disease using ...

HCA Healthcare, Inc. (NYSE:HCA), one of the nation's leading healthcare providers, today announced new research published in The New England Journal of Medicine (NEJM) demonstrating promising results ...

CRISPR Therapeutics wins FDA pediatric approval for Casgevy, boosting market potential and pipeline upside despite slow uptake. Click here to read more.